We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.
genetics: Archive
BioPharma Giants Print Fresh All-Time Highs
by Bryan Hayes
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
REGNPositive Net Change BMYNegative Net Change
biotechnology cancer cell-therapy coronavirus earnings genetics hospitals immuno-therapy investing large-cap medical medical-devices pharmaceuticals
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
PFEPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
REGNPositive Net Change GILDPositive Net Change CDMONegative Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines
What History Shows Us About 2022 Market Returns
by Bryan Hayes
What to Expect From the Markets In 2022
EWNegative Net Change MLABPositive Net Change SRTSPositive Net Change
biotechnology earnings genetics investing medical medical-devices pharmaceuticals smart-health
Bull Of The Day: Cutera (CUTR)
by Brian Bolan
This maker of lasers is posting some impressive growth and earnings numbers.
CUTRNegative Net Change
earnings genetics medical medical-devices
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
VRTXNegative Net Change MRNANegative Net Change CRSPNegative Net Change
biotechnology cell-therapy crispr genetics medical
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NEONegative Net Change EXASNegative Net Change NVTANegative Net Change NTRANegative Net Change GHNegative Net Change
biotechs cancer genetics genomics medical
Bear of the Day: Vericel (VCEL)
by Kevin Cook
Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside
VCELNegative Net Change UNHPositive Net Change MDWDPositive Net Change
biotechs genetics medical
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
EXASNegative Net Change ADPTNegative Net Change NVTANegative Net Change NTRANegative Net Change GHNegative Net Change
cancer coronavirus genetics genomics
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
BEAMNegative Net Change EDITNegative Net Change PBENegative Net Change NTLANegative Net Change CRSPNegative Net Change ARKGNegative Net Change GNOMNegative Net Change IDNANegative Net Change
biotechs etfs genetics
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
REGNPositive Net Change BEAMNegative Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change ARKGNegative Net Change GNOMNegative Net Change IDNANegative Net Change
etfs genetics
Bear of the Day: Guardant Health (GH)
by Kevin Cook
Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise
GHNegative Net Change EXASNegative Net Change
cancer genetics genomics medical
Moving Average Crossover Alert: Passage Bio (PASG)
by Zacks Equity Research
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
PASGNo Net Change
genetics medical
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
CRSPNegative Net Change EDITNegative Net Change ARKKNegative Net Change NTLANegative Net Change ARKGNegative Net Change
biofuels cancer genetics genomics medical
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
ILMNNegative Net Change EDITNegative Net Change NVTANegative Net Change ARKKNegative Net Change ARKGNegative Net Change
biotechs coronavirus genetics genomics
5 Top-Performing ARK ETFs Worth Your Attention Now
by Sweta Jaiswal, FRM
Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.
TDOCNegative Net Change PYPLPositive Net Change SQNegative Net Change ARKQNegative Net Change ARKWNegative Net Change ARKKNegative Net Change CRSPNegative Net Change ROKUNegative Net Change ARKGNegative Net Change GBTCNegative Net Change ARKFNegative Net Change
cloud-computing e-commerce etfs genetics internet
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Small-cap diagnostics player will grow sales 20%+ to over $310 million on COVID-19 testing and its mutations
VIVOPositive Net Change HOLXNegative Net Change QDELNegative Net Change EDITNegative Net Change CRSPNegative Net Change
coronavirus genetics genomics medical
The Innovative Future Of ETFs
by Daniel Laboe
Ark Invest is driving a new generation of actively managed ETFs
TSLANegative Net Change SQNegative Net Change ROKUNegative Net Change PRLBNegative Net Change NVTANegative Net Change CRSPNegative Net Change ARKKNegative Net Change
biotechs etfs genetics software tech-stocks
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
by Sweta Jaiswal, FRM
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
PBENegative Net Change ARKGNegative Net Change GNOMNegative Net Change IDNANegative Net Change
etfs genetics
Bear of the Day: Illumina (ILMN)
by Madeleine Johnson
The coronavirus pandemic has dampened this medical stock's earnings and outlook.
TMONegative Net Change ILMNNegative Net Change
genetics genomics
Bull of the Day: Quidel (QDEL)
by Kevin Cook
Multiple FDA approvals for new 15-minute COVID-19 antigen tests have estimates and shares rising sharply
QDELNegative Net Change MRNANegative Net Change
biotechs genetics medical
Profit from the Genomics Market Momentum With These ETFs
by Sweta Jaiswal, FRM
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
GSKPositive Net Change PBENegative Net Change ARKGNegative Net Change GNOMNegative Net Change IDNANegative Net Change
etfs genetics
Bull of the Day: Vertex Pharma (VRTX)
by Kevin Cook
While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth
VRTXNegative Net Change CRSPNegative Net Change
biotechs genetics genomics medical pharmaceuticals